Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Koleen Eisele"'
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::913466b83847b02760d8832503645b8d
https://doi.org/10.1158/1078-0432.22454691.v1
https://doi.org/10.1158/1078-0432.22454691.v1
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee29c5e6c07b5a865bf126f1bef796e
https://doi.org/10.1158/1078-0432.22454688
https://doi.org/10.1158/1078-0432.22454688
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45421649f6c61cc430618d3b84ec6afd
https://doi.org/10.1158/1078-0432.22454700
https://doi.org/10.1158/1078-0432.22454700
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53e5398bfcdac49fc14ce14291926781
https://doi.org/10.1158/1078-0432.22454697.v1
https://doi.org/10.1158/1078-0432.22454697.v1
Autor:
Shunqiang Li, Donald P. McDonnell, John D. Norris, Jin-Ping Lai, Robert Crowder, Jieya Shao, Elizabeth Griffin, Tina Primeau, Kim T. Arndt, Stephen G. Dann, Todd VanArsdale, Koleen Eisele, Holly M. Alley, Matthew J. Ellis, Suzanne E. Wardell
Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741a8d0744eed5814f3385c071daffe5
https://doi.org/10.1158/1078-0432.22454685
https://doi.org/10.1158/1078-0432.22454685
Autor:
Meirong Xu, Koleen Eisele, Douglas Carl Behenna, John Chionis, Sutton Scott Channing, Cathy Zhang, Ping Wei, Ravi Visswanathan, Stephen Dann, B Jessen, Robert M. Hoffman, Britton Boras, Kevin Daniel Freeman-Cook, Michael A. White, Qin Zhang, Brion W. Murray, Jing Yuan, Sacha Ninkovic, Scott L. Weinrich, Nanni Huser, Jim Solowiej, Nichol Miller, Todd VanArsdale, Chaoting Liu
Publikováno v:
Cancer Research. 79:P6-20
This abstract was withdrawn by the authors. Citation Format: Dann S, Chionis J, Eisele K, Zhang Q, Liu C, Yuan J, Miller N, Murray B, Xu M, Solowiej J, Wei P, Weinrich S, Sutton S, Behenna D, Ninkovic S, Hoffman R, Freeman-Cook K, Jessen B, Huser N,
Autor:
Xinmeng Jasmine Mu, Meirong Xu, Shahram Salek-Ardakani, Cinthia Costa-Jones, Lisa Nguyen, James Solowiej, David Looper, Scott L. Weinrich, Robert Louis Hoffman, Sutton Scott Channing, Sacha Ninkovic, Kephart Susan Elizabeth, Sherry Niessen, John Chionis, Jadwiga Bienkowska, Kevin Daniel Freeman-Cook, Rose Ann Ferre, John Lapek, Cecilia Oderup, Jordan Carelli, Cathy Zhang, Nanni Huser, Elizabeth A. McMillan, Asako Nagata, Martha A. Ornelas, Brion W. Murray, Douglas Carl Behenna, Koleen Eisele, Todd VanArsdale, Zhou Zhu, Zhengyan Kan, Chaoting Liu, Nichol Miller, Zehnder Luke Raymond, Michael A. White, Ying Ding, Nathan V. Lee, Jonathan Almaden, Qin Zhang, Tran Khanh Tuan, Ping Wei, Stephen Dann, Britton Boras, Tim S. Wang, Ravi Visswanathan, You-Ai He, Michele McTigue, Elizabeth Wilson
Publikováno v:
Cancer Cell. 39:1404-1421.e11
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analys
Autor:
Elizabeth A. McMillan, Koleen Eisele, Christina Adams, John Chionis, Timothy Affolter, Nichol Miller, Monica Ramstetter, Christopher P. Dillon, Jonathan Almaden, Lynn Wang, Tim S. Wang, Stephen Dann, Todd VanArsdale, Smitha Pillai
Publikováno v:
Cancer Research. 81:2960-2960
Overcoming checkpoints to cell cycle control is the basis for tumorigenesis and malignant growth. Therefore, models that recapitulate clinically relevant cell cycle deregulation enhance our understanding of defined tumors subsets. Specifically, pancr
Autor:
Romelia Salomon-Ferrer, Lawrence G. Lum, Todd VanArsdale, Nathan V. Lee, Andrew C. Wang, Aihua Zou, Koleen Eisele, Eric C. Greenwald, Catherine M. Ambler, Ana Flores-Bojorquez, Bryan Li, Carl Davis, Sergei Timofeevski, Martha A. Ornelas, Zhenxiong Wang, Penney L. Khamphavong, Samantha Elizabeth Greasley, Indrawan James Mcalpine, Michael F. Maestre, Jian Li, Ben Bolaños, Neil B. Grodsky, Yun Huang, Stephanie Scales, Ted William Johnson, Roksolana Melnychuk, Wade Diehl, Jon Oyer, Jacob DeForest, Sherry Niessen
Publikováno v:
Cancer Research. 81:330-330
Nomination of new oncology targets has been greatly aided by advances in genetic screening and profiling, but developing potent, selective small molecule inhibitors against these targets remains a resource intensive pursuit. To significantly de-risk
Autor:
Peter Olson, Koleen Eisele, Zhou Zhu, Valeria Fantin, Danan Li, David J. Shields, John Chionis, Todd VanArsdale, Chaoting Liu, Jing Yuan, Nathan V. Lee, Kim Arndt
Publikováno v:
Cancer Research. 76:P3-06
Estrogen receptor positive breast cancers show frequent deregulation of Cyclin D-CDK4/6 signaling. Combining CDK4/6 inhibitors with hormonal therapies produces clinical benefit, supporting drug approval of the first CDK4/6 inhibitor, Palbociclib, in